Wilson Sonsini Goodrich & Rosati represented the investors in the transaction. D3 Bio, Inc, a clinical-stage biotechnology announced its closing of a $62 million Series A financing...
D3 Bio’s $62 Million Series A Financing Round
D3 Bio’s $62 Million Series A Financing Round
Wilson Sonsini Goodrich & Rosati represented the investors in the transaction. D3 Bio, Inc, a clinical-stage biotechnology announced its closing of a $62 million Series A financing...
Celest Therapeutics’ Collaboration with Senti Biosciences
Wilson Sonsini Goodrich & Rosati represented Celest Therapeutics in the transaction. Celest Therapeutics (Shanghai) Co. Ltd (“Celest”) announced a collaboration with Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti...
Plutonian Acquisition Corp.’s $500 Million Business Combination with Big Tree Cloud
Wilson Sonsini Goodrich & Rosati and Global Law Office represented Plutonian in the transaction, Paul Hastings LLP, Commerce & Finance Law Offices and Maples Group represented...
Washington Commanders and Josh Harris’ Purchase and Sale Agreement
Wilson Sonsini Goodrich & Rosati represents Michael Li, owner of Range Group, a major investor in the buyer group for this transaction. The Washington Commanders and...
Aquaron Acquisition Corp.’s Merger with Bestpath
Wilson Sonsini advised Aquaron Acquisition Corp. on the deal. Bestpath (Shanghai) IoT Technology Co., Ltd. (Bestpath), a pioneering hydrogen fuel cell powered vehicle company in China,...
Oricell Therapeutics’ $45 Million Series B1 Financing
Wilson Sonsini Goodrich & Rosati advised RTW Investments on the deal. Oricell Therapeutics Co., Ltd, a China-based innovative pharmaceutical company committed to the development of tumor...
Envision Digital’s $210 Million Series A Financing
Wilson Sonsini Goodrich & Rosati advised Sequoia China on the deal. Envision Digital, the leading provider of Artificial Intelligence and Internet of Things (AIoT) software driving...
InSilico Medicine’s $255 Million Series C Financing
Wilson Sonsini Goodrich & Rosati advised InSilico Medicine on the deal. Ashurst represented Mirae Asset Capital. Hong Kong-based InSilico Medicine, a global leader in end-to-end artificial...